Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Halia Therapeutics

Request full access

Treating neurodegeneration and inflammatory diseases by targeting the nlrp3 inflammasome

Lehi, United StatesFounded 2017Biotech & Life Sciences

About Halia Therapeutics

Halia Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and neurodegenerative diseases. The company's research is centered on the NLRP3 inflammasome, a key component of the innate immune system that is implicated in the inflammatory response associated with numerous conditions.

Their therapeutic strategy involves the development of small molecule inhibitors that target the NLRP3 inflammasome. One of their lead candidates, HT-6184, is a first-in-class inhibitor designed to address 'metaflammation,' the chronic, low-grade inflammation linked to obesity and other metabolic diseases. The company is also advancing treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease through its LRRK2 inhibitor program, with its candidate HT-4253 targeting neuroinflammation.

The company's business model is based on the discovery and clinical development of novel drug candidates. By progressing these candidates through early-stage clinical trials, Halia Therapeutics aims to establish proof-of-concept and then seek partnerships or licensing agreements with larger pharmaceutical firms for late-stage development and commercialization. A notable collaboration includes receiving a 'Golden Ticket' from Novo Nordisk to advance research in obesity and metabolic syndromes.

Source: Dealroom company data

At a glance

Status
Operational
Employees
28
Open positions
2
Dealroom signal
83.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jan 2024 $30M $120M Todd Pedersen ↗
SERIES BOther financing Dec 2022 $12M $49M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Halia Therapeutics website traffic

Latest recorded traffic for Halia Therapeutics is 2.4K monthly website visits, up 192.7% over the last three months. Halia Therapeutics's team grew 7.7% over the past year.

Latest monthly visits2.4K 3-month web change+192.7% 1-year team growth+7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Halia Therapeutics in the Lehi ecosystem

Live from Dealroom

The Halia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Todd Pedersen
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States76.9%
🇦🇪 United Arab Emirates23.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Halia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Halia Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.